Stocktoria
AYTU BIOPHARMA, INC AYTU
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-10-20
AYTU BIOPHARMA, INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M |
| R&D expense | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M |
| Operating income | -$7.8M | -$1.6M | -$17.1M | -$109.9M | -$58.9M |
| Income tax | $437,000 | $2.1M | $0 | -$110,000 | $259,000 |
| Net income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M |
| EPS (diluted) | — | — | $-5.11 | $-74.01 | $-3.48 |
| Operating cash flow | -$1.9M | -$1.4M | -$5.1M | -$28.8M | -$26.0M |
| Free cash flow | -$2.2M | -$1.7M | — | — | — |
| Cash & equivalents | $31.0M | $20.0M | $23.0M | $19.4M | $49.6M |
| Inventory | $11.4M | $12.1M | $12.0M | $10.8M | $16.3M |
| Total assets | $124.2M | $118.1M | $136.5M | $137.6M | $265.7M |
| Total liabilities | — | — | $97.1M | $93.3M | $128.1M |
| Shareholders' equity | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M |
Source: SEC EDGAR filings · CIK 0001385818 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.